Kulkarni Samarth
SEC CIK 1682019 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | CEO, Dir | 255.5K | — | $48.21M | 85 | 2021-08-04 | 2026-03-23 |
Most active insiders at CRSP, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Kulkarni Samarth | CEO, Dir | — | $10.76M |
| 2 | Prasad Raju | CFO | — | $5.10M |
| 3 | KASINGER JAMES R. | GC, Sec | — | $1.27M |
| 4 | Behbahani Ali | Dir | — | $780.9K |
| 5 | Patel Naimish | Chief Medical Off | — | $362.6K |
Transactions 85
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-24 | 2026-03-23 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $46.78 | -10.0K | 255.5K | -4% | -$468.7K |
| D | 2026-03-24 | 2026-03-20 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +19.7K | 265.5K | +8% | — |
| D | 2026-03-17 | 2026-03-14 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +20.6K | 256.2K | +9% | — |
| D | 2026-03-17 | 2026-03-16 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $48.26 | -10.3K | 245.8K | -4% | -$499.4K |
| D | 2026-03-12 | 2026-03-10 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +19.2K | 245.4K | +9% | — |
| D | 2026-03-12 | 2026-03-11 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $52.80 | -9,798 | 235.6K | -4% | -$517.3K |
| D | 2026-02-20 | 2026-02-18 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +13.2K | 233.1K | +6% | — |
| D | 2026-02-20 | 2026-02-19 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $52.58 | -6,967 | 226.1K | -3% | -$366.3K |
| MT | 2026-01-22 | 2026-01-20+ | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale | $57.40 | -90.0K | 194.2K | -32% | -$5.17M |
| 2025-12-22 | 2025-12-18 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | G - Gift | $0.00 | -30.0K | 224.2K | -12% | $0 | |
| D | 2025-10-20 | 2025-10-16 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +100.0K | 305.1K | +49% | — |
| D | 2025-10-20 | 2025-10-17 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $67.91 | -50.9K | 254.2K | -17% | -$3.46M |
| D | 2025-10-15 | 2025-10-13 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +8,334 | 209.3K | +4% | — |
| D | 2025-10-15 | 2025-10-14 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $66.60 | -4,242 | 205.1K | -2% | -$282.5K |
| 2025-09-19 | 2025-09-17 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | G - Gift | $0.00 | -6,000 | 201.0K | -3% | $0 | |
| D | 2025-08-19 | 2025-08-18 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $58.15 | -13.1K | 207.0K | -6% | -$760.7K |
| D | 2025-08-19 | 2025-08-16 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +25.0K | 220.1K | +13% | — |
| D | 2025-03-24 | 2025-03-21 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $41.23 | -10.0K | 195.1K | -5% | -$413.6K |
| D | 2025-03-24 | 2025-03-20 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +19.7K | 205.1K | +11% | — |
| DM | 2025-03-12 | 2025-03-10+ | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +28.2K | 190.9K | +17% | — |
| DM | 2025-03-12 | 2025-03-11+ | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $42.70 | -14.4K | 185.4K | -7% | -$616.3K |
| T | 2025-02-21 | 2025-02-19 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale | $55.21 | -18.4K | 171.6K | -10% | -$1.01M |
| DMT | 2025-02-19 | 2025-02-18+ | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $54.21 | -18.6K | 196.9K | -9% | -$1.01M |
| DT | 2025-02-19 | 2025-02-18 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +13.2K | 208.5K | +7% | — |
| D | 2024-12-27 | 2024-12-24 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $16.21 | +13.8K | 195.3K | +8% | +$222.9K |
| T | 2024-12-04 | 2024-12-02 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale | $55.10 | -15.0K | 181.5K | -8% | -$826.5K |
| MT | 2024-11-13 | 2024-11-11 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale | $55.62 | -30.0K | 196.5K | -13% | -$1.67M |
| D | 2024-10-15 | 2024-10-14 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $46.28 | -4,293 | 226.5K | -2% | -$198.7K |
| D | 2024-10-15 | 2024-10-13 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +8,333 | 230.8K | +4% | — |
| 2024-08-12 | 2024-08-08 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | G - Gift | $0.00 | -100.0K | 222.5K | -31% | $0 | |
| DMT | 2024-04-17 | 2024-04-15 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $59.91 | -19.6K | 209.3K | -9% | -$1.17M |
| DT | 2024-04-17 | 2024-04-15 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +19.6K | 227.7K | +9% | +$374.4K |
| DMT | 2024-03-18 | 2024-03-15 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $72.48 | -20.0K | 208.1K | -9% | -$1.45M |
| DT | 2024-03-18 | 2024-03-15 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +20.0K | 228.1K | +10% | +$382.4K |
| DM | 2024-03-12 | 2024-03-11+ | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $77.04 | -14.4K | 208.1K | -6% | -$1.11M |
| DM | 2024-03-12 | 2024-03-10+ | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +28.2K | 213.5K | +15% | — |
| D | 2024-02-21 | 2024-02-18 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +13.2K | 200.6K | +7% | — |
| D | 2024-02-21 | 2024-02-20 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $79.67 | -6,370 | 194.3K | -3% | -$507.5K |
| DMT | 2024-02-16 | 2024-02-15 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $80.36 | -20.0K | 194.4K | -9% | -$1.61M |
| DT | 2024-02-16 | 2024-02-15 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +20.0K | 207.4K | +11% | +$382.4K |
| DMT | 2024-01-31 | 2024-01-29 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $60.51 | -50.0K | 188.1K | -21% | -$3.03M |
| DT | 2024-01-31 | 2024-01-29 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +50.0K | 237.4K | +27% | +$956.0K |
| DT | 2024-01-18 | 2024-01-16 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $62.50 | -20.0K | 187.4K | -10% | -$1.25M |
| DT | 2024-01-18 | 2024-01-16 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +20.0K | 207.4K | +11% | +$382.4K |
| DM | 2023-06-01 | 2023-05-30 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $64.87 | -25.0K | 399.1K | -6% | -$1.62M |
| D | 2023-06-01 | 2023-05-30 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +25.0K | 412.4K | +6% | +$478.0K |
| D | 2023-04-27 | 2023-04-25 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +25.0K | 412.4K | +6% | +$478.0K |
| DM | 2023-04-27 | 2023-04-25 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $50.67 | -25.0K | 387.4K | -6% | -$1.27M |
| D | 2023-03-31 | 2023-03-29 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +25.0K | 412.4K | +6% | +$478.0K |
| DM | 2023-03-31 | 2023-03-29 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $44.46 | -25.0K | 392.7K | -6% | -$1.11M |
| DM | 2023-03-14 | 2023-03-13 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | F - Tax | $43.22 | -9,444 | 382.5K | -2% | -$408.2K |
| DM | 2023-03-14 | 2023-03-10+ | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +20.8K | 387.8K | +6% | — |
| D | 2023-03-01 | 2023-02-27 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +25.0K | 401.0K | +7% | +$478.0K |
| DM | 2023-03-01 | 2023-02-27 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $48.25 | -25.0K | 376.0K | -6% | -$1.21M |
| D | 2023-02-22 | 2023-02-18 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +13.2K | 382.4K | +4% | — |
| D | 2023-02-22 | 2023-02-21 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | F - Tax | $48.26 | -6,373 | 376.0K | -2% | -$307.6K |
| DM | 2023-01-31 | 2023-01-27 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $51.47 | -25.0K | 392.3K | -6% | -$1.29M |
| D | 2023-01-31 | 2023-01-27 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +25.0K | 394.1K | +7% | +$478.0K |
| D | 2022-12-30 | 2022-12-28 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +25.0K | 394.1K | +7% | +$478.0K |
| DM | 2022-12-30 | 2022-12-28 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $40.93 | -25.0K | 369.1K | -6% | -$1.02M |
| D | 2022-12-08 | 2022-12-06 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $1.81 | +58.2K | 369.1K | +19% | +$105.4K |
| D | 2022-12-06 | 2022-12-03 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +40.0K | 330.3K | +14% | — |
| D | 2022-12-06 | 2022-12-05 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | F - Tax | $52.26 | -19.4K | 310.9K | -6% | -$1.01M |
| D | 2022-11-30 | 2022-11-28 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $19.12 | +25.0K | 315.3K | +9% | +$478.0K |
| DM | 2022-11-30 | 2022-11-28 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $54.03 | -25.0K | 292.6K | -8% | -$1.35M |
| DM | 2022-10-28 | 2022-10-26 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $54.81 | -25.0K | 290.3K | -8% | -$1.37M |
| DM | 2022-10-28 | 2022-10-26 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $16.84 | +25.0K | 315.3K | +9% | +$421.0K |
| D | 2022-09-30 | 2022-09-28 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $16.21 | +25.0K | 315.3K | +9% | +$405.2K |
| DM | 2022-09-30 | 2022-09-28 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $64.61 | -25.0K | 292.1K | -8% | -$1.62M |
| D | 2022-08-31 | 2022-08-29 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $16.21 | +25.0K | 315.3K | +9% | +$405.2K |
| DM | 2022-08-31 | 2022-08-29 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $66.85 | -25.0K | 311.2K | -7% | -$1.67M |
| DM | 2022-07-29 | 2022-07-27 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $75.91 | -25.0K | 308.3K | -7% | -$1.90M |
| DM | 2022-07-29 | 2022-07-27 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $15.00 | +25.0K | 298.6K | +9% | +$374.9K |
| DM | 2022-07-01 | 2022-06-29 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $61.59 | -25.0K | 290.3K | -8% | -$1.54M |
| D | 2022-07-01 | 2022-06-29 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $12.57 | +25.0K | 315.3K | +9% | +$314.2K |
| DM | 2022-03-14 | 2022-03-10+ | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +20.8K | 290.9K | +8% | — |
| DM | 2022-03-14 | 2022-03-11+ | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | F - Tax | $61.92 | -9,640 | 285.4K | -3% | -$596.9K |
| D | 2021-12-22 | 2021-12-20 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $1.81 | +17.8K | 279.1K | +7% | +$32.1K |
| D | 2021-12-07 | 2021-12-06 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | F - Tax | $69.17 | -37.8K | 261.3K | -13% | -$2.62M |
| D | 2021-12-07 | 2021-12-03 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | — | +80.0K | 299.2K | +37% | — |
| 2021-12-03 | 2021-12-01 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | F - Tax | $75.10 | -779 | 219.2K | -0.4% | -$58.5K | |
| D | 2021-10-18 | 2021-10-15 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $1.81 | +33.0K | 219.9K | +18% | +$59.7K |
| 2021-09-03 | 2021-09-01 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | F - Tax | $124.83 | -787 | 186.9K | -0.4% | -$98.2K | |
| DM | 2021-08-06 | 2021-08-04+ | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | M - OptEx | $12.57 | +30.0K | 189.2K | +19% | +$377.1K |
| DM | 2021-08-06 | 2021-08-04+ | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | CEO, Dir | S - Sale+OE | $128.78 | -30.0K | 210.5K | -12% | -$3.86M |
Purchase Sale Sale after option exercise All abbreviations